

## References

### Y-5049

1. Shinohara E, Whaley JT. Last reviewed: March 3, 2020. <https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me>. Accessed June 3, 2021
2. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. *Radiat Oncol*. May 22 2019; 14(1): 84. PMID 31118042
3. Boda-Heggemann J, Hofheinz RD, Weiss C, et al. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. *Int J Radiat Oncol Biol Phys*. Nov 15 2009; 75(4): 1187-95. PMID 19409725
4. Boda-Heggemann J, Weiss C, Schneider V, et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. *Strahlenther Onkol*. May 2013; 189(5): 417-23. PMID 23558673
5. Fuller CD, Dang ND, Wang SJ, et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. *Radiother Oncol*. Aug 2009; 92(2): 249-54. PMID 19324442
6. Lee KJ, Yoon HI, Chung MJ, et al. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. *Gut Liver*. Mar 2016; 10(2): 303-9. PMID 26470767
7. Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. *Pract Radiat Oncol*. Mar-Apr 2016; 6(2): 78-85. PMID 26577010
8. Lin Y, Chen K, Lu Z, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. *Radiat Oncol*. Sep 14 2018; 13(1): 177. PMID 30217165
9. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. *J Clin Oncol*. Aug 20 2018; 36(24): 2538-2544. PMID 29989857
10. Naik A, Gurjar OP, Gupta KL, et al. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. *Cancer Radiother*. Jul 2016; 20(5): 370-6. PMID 27368915

11. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. *Int J Radiat Oncol Biol Phys.* Nov 01 2013; 87(3): 542-8. PMID 24074927
12. Shih KK, Hajj C, Kollmeier M, et al. Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. *Gynecol Oncol.* Oct 2016; 143(1): 18-21. PMID 27486131
13. Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. *J Formos Med Assoc.* Dec 2014; 113(12): 949-55. PMID 24144528
14. Rattan R, Kapoor R, Bahl A, et al. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. *Ann Transl Med.* Feb 2016; 4(4): 70. PMID 27004217
15. Sun Z, Adam MA, Kim J, et al. Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. *J Gastrointest Surg.* Jan 2017; 21(1): 106-111. PMID 27510332
16. Huang CM, Huang MY, Tsai HL, et al. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. *J Radiat Res.* Mar 01 2017; 58(2): 247-259. PMID 27738080
17. Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. *Gastrointest Cancer Res.* Mar 2013; 6(2): 39-45. PMID 23745158
18. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiother Oncol.* May 2013; 107(2): 189-94. PMID 23692961
19. Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?. *Radiat Oncol.* Nov 29 2012; 7: 201. PMID 23190693
20. Devisetty K, Mell LK, Salama JK, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. *Radiother Oncol.* Nov 2009; 93(2): 298-301. PMID 19717198

21. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. *Int J Radiat Oncol Biol Phys*. Dec 01 2010; 78(5): 1413-9. PMID 20231064
22. Xu D, Li G, Li H, et al. Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis. *Medicine (Baltimore)*. Aug 2017; 96(31): e7685. PMID 28767597
23. Lan K, Zhu J, Zhang J, et al. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. *Radiother Oncol*. Aug 2020; 149: 228-235. PMID 32474127
24. Ito M, Kodaira T, Tachibana H, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. *Head Neck*. Dec 2017; 39(12): 2406-2415. PMID 28960561
25. Haefner MF, Lang K, Verma V, et al. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. *Radiat Oncol*. Aug 15 2017; 12(1): 131. PMID 28810885
26. National Comprehensive Cancer Network. Gastric Cancer. Version. 2.2019. Updated May 13, 2020. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf). Accessed June 3, 2021.
27. National Comprehensive Cancer Network. Hepatobiliary Cancers. Version. 2.2021. Updated June 1, 2020. [https://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf). Accessed June 3, 2021.
28. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. Version. 2.2021. Updated February 25, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf). Accessed June 3, 2021.
29. National Comprehensive Cancer Network. Cervical Cancer. Version. 1.2020. Updated October 2, 2020. [https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf). Accessed June 3, 2021.
30. National Comprehensive Cancer Network. Uterine Neoplasms. Version 2.2021. Updated March 6, 2020. [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf). Accessed June 3, 2021.
31. National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer.

- Version.1.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed August 17, 2021.
32. National Comprehensive Cancer Network. Anal Carcinoma. Version. 2.2020. Updated February 16, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf). Accessed June 3, 2021.
33. National Comprehensive Cancer Network. Rectal Cancer. Version.1.2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). Accessed August 17, 2021.
34. National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. Version 2.2021. Updated March 9, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf). Accessed June 4, 2021.
35. Chino J, Annunziata CM, Beriwal S, et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol*. Jul 2020; 10(4): 220-234. PMID 32473857
36. Wo JY, Anker CJ, Ashman JB, et al. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Pract Radiat Oncol*. Jan-Feb 2021; 11(1): 13-25. PMID 33097436